美国参议员伯尼-桑德斯（Bernie Sanders）周二表示，他已收到所有主要药房福利管理机构的承诺，如果诺和诺德公司降低其畅销糖尿病和减肥药品的上市价格，他们将扩大这些药品的承保覆盖范围。

今天，在美国参议院卫生、教育、劳工和养老金委员会的听证会上，诺和诺德公司CEO Lars Jorgensen将面对参议员Bernie Sanders关于公司减肥和糖尿病药物定价的质询。这些药物Wegovy和Ozempic在美国的定价显著高于一些欧洲国家，美国的挂牌价分别为每月供应量1,349.02美元和935.77美元。 作为委员会主席的Sanders预计将就向美国付款方收取比其他任何国家更高的药 ...

Lars Fruergaard Jørgensen, Novo Nordisk's CEO, says his company is working to expand manufacturing to meet the supply ...

Sen. Bernie Sanders grilled Novo Nordisk's CEO Lars Jorgensen over the cost of the company's weight loss and diabetes ...

Senators grilled Novo Nordisk CEO Lars Jorgensen at a hearing on Tuesday about the cost of diabetes drug Ozempic and weight ...

The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...

The Senate Health, Education, Labor and Pension committee, led by Vermont Sen. Bernie Sanders, is hearing testimony from Novo ...

WASHINGTON — Senate health committee chair Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo ...

The maker of diabetes and weight-loss drugs Ozempic and Wegovy was in the hot seat Tuesday as Vermont Sen. Bernie Sanders ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will defend the prices of his company’s mega-blockbuster obesity and Type 2 ...

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

While Congress debates the high cost of brand-name diabetes and weight loss drugs, Atlanta doctors are selling lower-cost alternatives made by compounding pharmacies.